Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
Early measurable residual disease (MRD) negativity and timing of relapse are crucial for risk stratification in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) treated with blinatumomab and/or inotuzumab ozogamic
A multicenter real-world study demonstrates that combining venetoclax with high-dose cytarabine and mitoxantrone significantly improves remission and survival rates in relapsed/refractory AML, with validated risk factors guiding prognostica
This retrospective study assesses the efficacy and safety of pemetrexed, alone or combined with carboplatin, as salvage therapy for advanced thyroid cancer, showing promising response rates comparable to current second-line treatments.
A landmark multicenter study indicates that salvage focal therapy (sFT) achieves long-term cancer-specific survival comparable to salvage radical prostatectomy (sRP) while significantly lowering the risk of major perioperative complications
A multicentre phase 2 trial demonstrates that the combination of venetoclax and azacitidine achieves a 76% overall response rate in relapsed or refractory T-ALL, offering a manageable and effective alternative for a patient population with
Phase 2b data show olorofim has activity and acceptable tolerability in patients with invasive fungal disease and limited options, including azole‑resistant Aspergillus and intrinsically resistant moulds, supporting further controlled studi